BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price ...

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen ...

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.

As the European Lung Cancer Congress prepares to convene in Copenhagen, BioNTech SE is shifting investor focus toward its expanding oncology portfolio. New clinical data for its antibody-drug ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...